Cartesian Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Cartesian Therapeutics, Inc. (RNAC) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$22.10 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-03-28
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$5.20M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$20.21M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-12-31 was -$2.91M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-09-30 was -$1.22M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$22.10M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$4.68M.
- Cartesian Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$227.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-28 | -$25.41M derived: sum of 2 quarters · filed 2017-03-28 | -$22.10M 10-K · filed 2017-03-28 | |
| 2016-09-30 | -$20.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$16.90M 10-Q · filed 2016-11-10 | ||
| 2016-06-30 | $3.31M 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-28 | -$4.13M derived: sum of 2 quarters · filed 2017-03-28 | -$4.68M 10-K · filed 2017-03-28 | |
| 2015-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$1.77M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | -$553.00K 10-Q · filed 2016-08-09 | |||
| 2014-12-31 | -$227.00K 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |